Is MOLN or NVAX more undervalued in 2026?

CirclFi compares Molecular Partners AG (MOLN) and Novavax, Inc. (NVAX) using 13 institutional-grade valuation models. MOLN has a Quality of Company score of 4.7/10 while NVAX scores 6.4/10.

Which is a better buy — MOLN or NVAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MOLN and NVAX valuations compare?

MOLN at $4.20 and NVAX at $10.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MOLN vs NVAX Valuation Comparison 2026 — Intrinsic Value Analysis

MOLN

Biological Products, (No Diagnostic Substances)

Molecular Partners AG

Quality

4.7

out of 10

Value Trap

LOW

Price

$4.20

Last close

Models

8/13

Active

NVAX

Biological Products, (No Diagnostic Substances)

Novavax, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$10.97

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	MOLN Fair Value	MOLN Upside	NVAX Fair Value	NVAX Upside
Bayesian DCF	Intrinsic	$1.13	-73.1%	$1.33	-87.9%
Earnings Power Value	Intrinsic	—	—	$2.46	-69.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.69	-59.7%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MOLN vs NVAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MOLN vs NVAX — Which Stock Is More Undervalued?

NVAX scores higher with a 6.4/10 quality rating vs MOLN's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Molecular Partners AG (MOLN) and Novavax, Inc. (NVAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MOLN currently trades at $4.20 with a QOC of 4.7/10, while NVAX trades at $10.97 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).